<DOC>
	<DOCNO>NCT00093366</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , work different way stop cancer cell divide stop grow die . Biological therapy etanercept may interfere growth cancer cell . Combining chemotherapy biological therapy may kill cancer cell . PURPOSE : This phase I/II trial study side effect give arsenic trioxide together etanercept see well work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Arsenic Trioxide Etanercept Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency hematologic response patient intermediate-2 high-risk myelodysplastic syndrome ( MDS ) treat arsenic trioxide etanercept . - Determine efficacy regimen patient intermediate-1 low-risk MDS refractory anti-thymocyte globulin etanercept protocol FHCRC-1872 . - Correlate result ex vivo vitro study phenotypic , cytogenetic , functional disease characteristic vivo treatment response patient treat regimen . - Determine parameter associate high probability disease response patient treat regimen . OUTLINE : This pilot study . Patients receive arsenic trioxide IV 1-4 hour day 1-5 week 1 twice weekly week 2-12 course 1 ( twice weekly week 1-12 course 2 ) . Patients also receive etanercept subcutaneously twice weekly week 1 , 2 , 5 , 6 , 9 , 10 . Treatment repeat every 12 week 2 course absence disease progression unacceptable toxicity . Patients follow 3 month . PROJECTED ACCRUAL : A total 15-32 patient accrue study within 8-18 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) meet 1 follow criterion : Intermediate2 highrisk disease Intermediate1 lowrisk disease refractory antithymocyte globulin etanercept protocol FHCRC1872 Not eligible stem cell transplantation follow reason : Suitable bone marrow donor available Ineligible transplantation protocol Not willing undergo transplantation PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 500/mm^3 Hepatic Not specify Renal Not specify Cardiovascular No evidence cardiac arrhythmia No evidence congestive heart failure QTc interval â‰¤ 460 msec Pulmonary No pneumonia Other Potassium &gt; 4.0 mEq/L ( supplemental electrolyte allow ) Magnesium &gt; 1.8 mg/dL ( supplemental electrolyte allow ) No history anaphylactic reaction arsenic trioxide No active severe infection ( e.g. , septicemia ) within past 2 week No severe disease would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior hematopoietic stem cell transplantation More 4 week since prior hematopoietic growth factor MDS More 4 week since prior immunomodulatory therapy MDS No concurrent hematopoietic growth factor MDS No concurrent immunomodulatory therapy MDS Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 4 week since prior cytotoxic therapy MDS More 4 week since prior experimental therapy MDS No concurrent cytotoxic therapy MDS No concurrent experimental therapy MDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
</DOC>